| Literature DB >> 30297237 |
Nicolas Penel1, Sophie El Bedoui2, Yves-Marie Robin3, Gauthier Decanter4.
Abstract
Dematofibrosarcoma protuberans (DFSP) are very rare (1 to 4 incident cases per million of inhabitants). The local spreading of DFSP is underestimated. The histological diagnosis is challenging but we now know a specific marker (translocation t(17;22)(q22;q13) (COL1A1;PDGFB)). The risk of metastatic relapse is low (and related to fibrosarcoma component); the risk of local relapse depends on the quality of surgery. Management of localized DFSP is based on large resection with meticulous analysis of margins (with or without Mohs microsurgery). Advanced stages not amenable to surgery or metastatic DFSP (with presence of COL1A1;PDGFB) are best treated with imatinib. Locally advanced DFSP potentially amenable to curative intent surgery could be treated with imatinib as neo-adjuvant treatment. The management of these tumours requires multidisciplinary expertise.Entities:
Keywords: Dermatofibrosarcoma; Dermatofibrosarcome; Fusion gene; Imatinib; Marges; Margins; Microchirurgie de Mohs; Mohs microsurgery; Transcrit de fusion
Mesh:
Substances:
Year: 2018 PMID: 30297237 DOI: 10.1016/j.bulcan.2018.08.008
Source DB: PubMed Journal: Bull Cancer ISSN: 0007-4551 Impact factor: 1.276